<i>Retracted</i>: Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4

Zhang, Min; Yan, Li; Wang, Guijie; Jin, Ronghui

doi:10.1002/jcp.27631

Cited by 24 publications

(13 citation statements)

References 37 publications

(70 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Evidence from previous studies also suggest that resistin could be an essential modulator in tumor growth and chemoresistance. Zhang M et al [26], for instance, showed that injection of resistin significantly accelerated subcutaneous tumor growth and chemoresistance in mice. Similarly, Deshmukh et al [27] showed that resistin induced breast cancer cell growth and aggressiveness through increased expression and phosphorylation of signal transducer and activator of transcription 3 (STAT3).…”

Section: Plos Onementioning

confidence: 99%

Resistin is a risk factor for all-cause mortality in elderly Finnish population: A prospective study in the OPERA cohort

Parkkila¹,

Kiviniemi²,

Tulppo³

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

Objective Resistin is a small, cysteine-rich proinflammatory molecule that is primarily secreted by peripheral blood mononuclear cells and macrophages in humans. Previous studies have shown resistin to participate in various pathological processes including atherosclerosis and cancer progression but not many studies have assessed the role of resistin as a risk factor for all-cause mortality. The objective of this prospective study was to evaluate whether resistin predicts mortality among elderly Finnish people. Methods The study population consisted of 599 elderly (71.7 ± 5.4 years) patients and the follow-up was approximately six years. A thorough clinical examination including anthropometric and other clinical measurements such as blood pressure as well as various laboratory parameters (including resistin) was conducted at baseline. Results After the follow-up, 65 (11%) of the patients died. Resistin was a significant risk factor for all-cause mortality (HR 3.02, 95% CI: 1.64–5.56, p<0.001) when the highest tertile was compared to the lowest. Resistin remained as a significant risk factor even after adjusting for various covariates such as age, sex, systolic blood pressure, smoking habits, alcohol consumption, medications (antihypertensive, lipid-lowering, glucose-lowering), hsCRP and leisure time physical activity. Receiver operating characteristic (ROC) curve analysis for resistin demonstrated area under the curve (AUC) of 0.656 (95% CI: 0.577–0.734), p<0.001 and an optimal cutoff value of 12.88 ng/ml. Conclusions Our results indicate that resistin is a significant risk factor for all-cause mortality among elderly Finnish subjects, independent from traditional cardiovascular risk factors.

show abstract

Section: Plos Onementioning

confidence: 99%

Resistin is a risk factor for all-cause mortality in elderly Finnish population: A prospective study in the OPERA cohort

Parkkila¹,

Kiviniemi²,

Tulppo³

et al. 2021

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Resistin can also contribute to pancreatic cancer pathogenesis, since its levels are increased in pancreatic cancer patients and correlate positively with tumor grades. Moreover, the Resistin receptors CAP1 and TLR4 mediate the effects of Resistin on cancer cells through activation of STAT3 (signal transducer and activator of transcription 3) and are implicated in the resistance to chemotherapy (Zhang et al, 2019).…”

Section: Cap1 At the Crossroads Of Metabolism And Cancermentioning

confidence: 99%

CAPt’n of Actin Dynamics: Recent Advances in the Molecular, Developmental and Physiological Functions of Cyclase-Associated Protein (CAP)

Rust

Khudayberdiev

Pelucchi

et al. 2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Cyclase-associated protein (CAP) has been discovered three decades ago in budding yeast as a protein that associates with the cyclic adenosine monophosphate (cAMP)producing adenylyl cyclase and that suppresses a hyperactive RAS2 variant. Since that time, CAP has been identified in all eukaryotic species examined and it became evident that the activity in RAS-cAMP signaling is restricted to a limited number of species. Instead, its actin binding activity is conserved among eukaryotes and actin cytoskeleton regulation emerged as its primary function. However, for many years, the molecular functions as well as the developmental and physiological relevance of CAP remained unknown. In the present article, we will compile important recent progress on its molecular functions that identified CAP as a novel key regulator of actin dynamics, i.e., the spatiotemporally controlled assembly and disassembly of actin filaments (Factin). These studies unraveled a cooperation with ADF/Cofilin and Twinfilin in F-actin disassembly, a nucleotide exchange activity on globular actin monomers (G-actin) that is required for F-actin assembly and an inhibitory function towards the F-actin assembly factor INF2. Moreover, by focusing on selected model organisms, we will review current literature on its developmental and physiological functions, and we will present studies implicating CAP in human pathologies. Together, this review article summarizes and discusses recent achievements in understanding the molecular, developmental and physiological functions of CAP, which led this protein emerge as a novel CAPt'n of actin dynamics.

show abstract

“…A recent study reported that elevated serum levels of resistin, another adipocyte-secreted factor, correlated positively with tumor grade in PC patients [88]. Inhibition of resistin receptors, adenylyl cyclase-associated protein 1 (CAP1) and toll-like receptor 4 (TLR4) in PC cell lines were associated with reduced proliferation, migration and invasion [88].…”

Section: Other Adipokinesmentioning

confidence: 99%

The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective

Brocco

Florio

Lellis

et al. 2020

Cancers

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a lethal malignancy with rising incidence and limited therapeutic options. Obesity is a well-established risk factor for PC development. Moreover, it negatively affects outcome in PC patients. Excessive fat accumulation in obese, over- and normal-weight individuals induces metabolic and inflammatory changes of adipose tissue microenvironment leading to a dysfunctional adipose “organ”. This may drive the association between abnormal fat accumulation and pancreatic cancer. In this review, we describe several molecular mechanisms that underpin this association at both local and systemic levels. We focus on the role of adipose tissue-derived circulating factors including adipokines, hormones and pro-inflammatory cytokines, as well as on the impact of the local adipose tissue in promoting PC. A discussion on potential therapeutic interventions, interfering with pro-tumorigenic effects of dysfunctional adipose tissue in PC, is included. Considering the raise of global obesity, research efforts to uncover the molecular basis of the relationship between pancreatic cancer and adipose tissue dysfunction may provide novel insights for the prevention of this deadly disease. In addition, these efforts may uncover novel targets for personalized interventional strategies aimed at improving the currently unsatisfactory PC therapeutic options.

show abstract

Retracted: Resistin effects on pancreatic cancer progression and chemoresistance are mediated through its receptors CAP1 and TLR4

Cited by 24 publications

References 37 publications

Resistin is a risk factor for all-cause mortality in elderly Finnish population: A prospective study in the OPERA cohort

Resistin is a risk factor for all-cause mortality in elderly Finnish population: A prospective study in the OPERA cohort

CAPt’n of Actin Dynamics: Recent Advances in the Molecular, Developmental and Physiological Functions of Cyclase-Associated Protein (CAP)

The Role of Dysfunctional Adipose Tissue in Pancreatic Cancer: A Molecular Perspective

Contact Info

Product

Resources

About